Walmart’s Fashion Recovery and the GLP-1 Wardrobe Wave Are About to Collide
Walmart’s former CEO Doug McMillon said something on a May 2024 earnings call that the company’s fashion team had probably known for years. “We punched below our weight on general merchandise, specifically in apparel and home, for a really long time, maybe forever,” he told analysts. It was an unusual admission mid-recovery, and it captured the scale of the problem Denise Incandela, Walmart’s EVP of Fashion, had been hired in 2017 to fix. By the time McMillon said it, Incandela had already spent seven years overhauling the business, launching or relaunching 10 private brands, bringing in designer Brandon Maxwell as creative director, modernizing store merchandising, and targeting a price corridor from $15 to $40 where Walmart had historically underperformed.
The results have arrived, unevenly but unmistakably. General merchandise ended an 11-quarter sales decline starting in Q2 of fiscal 2026. Fashion grew unit sales over 5% in every month of Q3. By Q4, incoming CEO John Furner called fashion a “bright spot” on the earnings call, and CFO John David Rainey said on that same call that almost all of the category’s mid-single-digit growth came from households earning over $100,000. At NRF’s Big Show in January 2026, Incandela told attendees that 40% of Walmart Fashion customers now belong to that income tier. “Our $100K-plus household income customers are increasing dramatically,” she said, “because they’re looking at Walmart for the first time for fashion.”
That customer, higher income, newer to Walmart’s apparel floor, still being converted, is the same customer now driving one of the most significant demand shifts the U.S. apparel industry has seen in years.
The Income Cohort Walmart Has Been Winning Is the One Most Likely to Need New Clothes
About 23% of all U.S. households were using GLP-1 medications as of September 2025, up four percentage points from the prior year, according to Circana. Bernstein’s annual shopper survey found GLP-1 adoption grew from 11% of Americans in November 2024 to 16% by November 2025, before oral pills entered the market. JPMorgan estimates the number of Americans on GLP-1 treatment could reach 30 million by 2030, up from 10 million today.
Bernstein analyst Aneesha Sherman, covering U.S. apparel and specialty retail, noted in a late March report that GLP-1 users have tended to skew higher income than the general population, and that this income skew may push them toward more expensive items within whatever assortment they are shopping. A Circana survey from January found that 80% of active GLP-1 users anticipate needing new clothing due to size changes, and 55% have already purchased new clothing or footwear. Bernstein estimates that if users drop roughly three sizes and purchase five to eight items per size drop, the result is somewhere between 150 million and 700 million incremental apparel units per year, up to $13 billion in additional annual spending, based on Euromonitor’s average U.S. apparel selling price of about $18.
The customer Walmart has been winning in fashion, higher income, newly engaged, value-oriented, is arriving at precisely the moment that customer has the most structural reason to buy new clothes in years. Suppliers should treat that overlap as a planning input, not a market observation.
Walmart’s Pharmacy Counter Creates a Capture Mechanism No Apparel Competitor Has
The demographic overlap is meaningful. The pharmacy position is what makes it specific to Walmart.
In October 2025, Walmart and Eli Lilly announced a partnership making Zepbound available for cash-pay pickup at Walmart pharmacies nationwide, nearly 4,600 locations, at a self-pay price at least 50% below the list price of other GLP-1 medications, according to the Lilly press release. In January 2026, Sam’s Club began dispensing oral Wegovy at $149 per month, making the Walmart ecosystem the only mass retail pharmacy footprint carrying both major branded GLP-1 drugs at discounted self-pay pricing simultaneously. Walmart said in September 2025 that it had become the first retailer to deliver refrigerated prescriptions, including GLP-1 injectables, alongside groceries and everyday essentials in a single order.
Sherman told CNBC that big-box retailers with pharmacies hold a specific advantage: customers may add clothing to their basket during the same visit they pick up their medication. At Walmart, that mechanism is physical. A customer picking up Zepbound at the pharmacy counter is already in the building. For delivery customers, the basket opportunity moves to the app. Neither scenario is available to T.J. Maxx, Stitch Fix, Lululemon, or any other retailer named by Bernstein as a likely GLP-1 beneficiary. Those retailers will compete for the same wardrobe refresh. Walmart is the only one with a reason for that customer to show up before the decision to shop for clothes has been made.
The Size Curve Is Moving Faster Than Most Assortments Are Built to Handle
The sizing shift has been clearest in intimate apparel, where fit tolerances leave no room for a size or two of slack. Circana has documented declining sales of larger bra band sizes (42+) and D cup sizes, with mid-range sizes gaining share. Victoria’s Secret CEO Hillary Super attributed a roughly 3% swing downward in bra band and underwear sizes directly to GLP-1 adoption, in a February interview with Fortune. Circana apparel advisor Kristen Classi-Zummo told CNBC that bras are the leading indicator because fit is non-negotiable, and that over the last three months the same trend has spilled into women’s apparel broadly, with plus-sized clothing losing share to women’s apparel around size 12 and under. She expects GLP-1-driven demand to accelerate over the next six months.
For 1P suppliers, the size curve is the most immediate planning variable. Walmart’s own No Boundaries private label was relaunched in 2024 with sizing from XXS to 5X in women’s, covering the full transition range. Branded suppliers whose size runs compress at the high end of the plus range may find themselves underrepresented during precisely the period when GLP-1 users are actively moving through multiple sizes. The question for the next line review is whether the current size distribution was calibrated for a market trending toward plus-sized, because that market is now trending the other way.
For 3P Marketplace sellers, the same shift shows up differently. Apparel categories with the most GLP-1 momentum, basics, casual pants, denim, activewear, are also the most competitive categories on Walmart’s Marketplace. A macro demand tailwind does not improve conversion on a listing with thin reviews, incomplete size availability, or weak imagery. Sellers in those categories should be auditing size-run completeness and listing quality now, before Circana’s projected acceleration shows up in search behavior.
The Full Demand Wave Has Not Arrived Yet
Destination XL CEO Harvey Kanter told analysts on the company’s March earnings call that as many as 25% of his customers are currently on GLP-1 medications, and that they are buying $20 shirts instead of $120 ones while the weight loss continues, waiting to refresh their wardrobes until they reach goal weight. “Right now, we’re in a pattern where they’re losing weight and they’re trying not to buy clothes until they’re done with that journey,” he said. ThredUp reported that purchase volume for large, extra large, and plus-sized apparel combined grew 6% in March 2026 compared to the prior year, even as purchase volume for small and medium sizes dropped 6% over the same period, a pattern consistent with people selling the old wardrobe before they have finished buying the new one.
The collision is forming, not complete. Bernstein’s $13 billion estimate may be conservative, the firm noted, given the income skew of current GLP-1 users. Circana projects overall U.S. apparel industry sales will grow only 0.4% this year, which makes any structural demand driver worth mapping precisely rather than broadly.
Walmart’s apparel business is not finished rebuilding. On the November 2025 earnings call, Rainey said the fashion strength was “more of a macro phenomenon than anything.” GlobalData analyst Neil Saunders told Modern Retail the company is “early on in this process.” What Walmart does have is genuine momentum in exactly the customer cohort that is about to have the most compelling reason to buy new clothes, and a pharmacy footprint that puts those customers in the store or the app before they have decided to shop for them. For suppliers building fiscal 2027 assortment plans, the relevant question is not whether this collision is coming. It is whether their size curve, price positioning, and listing quality will be ready when it does.
Winning With Walmart
Winning With Walmart is an independent platform for suppliers, sellers, solution providers, and industry experts.
Articles are developed by staff editors, contributing experts, and trusted partners.
Some are researched and drafted with the assistance of AI tools and are reviewed, fact-checked, and edited by Winning With Walmart editors before publication.
Editorial judgment, sourcing decisions, and final approval rest with the publication's human editors in every case.
We are committed to accuracy and fairness. If you believe this article contains an error, we welcome your feedback.